Skip to content
Search

Latest Stories

Regulator strikes out two-year requirement as registered pharmacist for IP training in Northern Ireland

The Council of the Pharmaceutical Society NI (PSNI) to remove the two-year requirement as a registered pharmacist to have an Independent Prescriber (IP) annotation on the pharmacy register in Northern Ireland.

It has further endorsed that the two-year requirement for entry onto stand-alone pharmacist independent prescribing courses be removed and replaced with an assessment before admission, by course providers, based upon guidance provided by the regulator.


In conjunction with the Department of Health, the PSNI will now work towards a further public consultation on the necessary legislative changes.

Dr Jim Livingstone, president of the PSNI, said: “The Department of Health has set a clear direction which will see pharmacist independent prescribers becoming increasingly important in the delivery of pharmacy services in Northern Ireland. Our role is to protect the public, but we are clear that our regulatory objective should not be an unnecessary barrier to the development of the profession and enhanced services being provided to the public."

The council’s recent public consultation outlined proposals on changes to the entry requirements for standalone independent prescribing courses and annotation as an IP on the register. The proposals sought to strike a right balance between protecting the public, whilst not placing disproportionate regulatory barriers in the way of developing services.

“I am pleased that our proposals were broadly supported,” Dr Livingstone said, adding: “Removing the two-year period before being annotated on the Register is necessary to deliver wider reforms to pharmacy education. We will continue to work with the Department of Health, to move towards a public consultation on the necessary legislative changes.

“We acknowledge the feedback received, that some further clarification and guidance is required in certain areas, and we have committed to working with our colleagues in the GPhC to develop guidance for course providers and others.

“We are also committed to exploring what additional support might be needed for independent prescribers in relation to post-registration education and professional development. We will take this work on as part of our partnership with the GPhC on the UK wide post-registration assurance of practise group. Ensuring that there is appropriate engagement and involvement with local stakeholders.

“We had several excellent responses to this consultation, which raised important issues. A number of these issues related to the wider education reform agenda and are outside the immediate responsibility of the Regulator. We have, however, committed to presenting our consultation report to the Education Reform Implementation Group, which is progressing these wider reforms in Northern Ireland.”

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less